Evidence map›Paper›PMID 36076912›Full record

ArticleInternational journal of molecular sciences2022

Study of the Ghrelin/LEAP-2 Ratio in Humans and Rats during Different Phases of Pregnancy.

Maria Fernanda Garcés, Julieth Daniela Buell-Acosta, Edith Ángel-Müller, Arturo José Parada-Baños, Jaidy Acosta-Alvarez, Harold Felipe Saavedra-López, Roberto Franco-Vega, Luis Miguel Maldonado-Acosta, Franklin Escobar-Cordoba, Keydy Vásquez-Romero and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. LEAP2 in Physiology-A Narrative Review.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Maria Fernanda GarcésDepartment of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.
Julieth Daniela Buell-AcostaDepartment of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.ORCID 0000-0002-3000-2440
Edith Ángel-MüllerDepartment of Gynecology and Obstetrics, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.ORCID 0000-0001-8302-5841
Arturo José Parada-BañosDepartment of Gynecology and Obstetrics, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.ORCID 0000-0003-2810-287X
Jaidy Acosta-AlvarezDepartment of Morphology, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.
Harold Felipe Saavedra-LópezEndocrinology Unit, Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.
Roberto Franco-VegaEndocrinology Unit, Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.
Luis Miguel Maldonado-AcostaEndocrinology Unit, Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.
Franklin Escobar-CordobaPsychiatry Department, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.ORCID 0000-0002-0561-4883
Keydy Vásquez-RomeroCentro de Biomodelos CeBio, Departamento de Ciencias Biológicas, Universidad de los Andes, Bogotá 111711, Colombia.
Ezequiel LacunzaCentro de Investigaciones Inmunológicas Básicas y Aplicadas (CINIBA), Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata 1900, Argentina.ORCID 0000-0002-6731-9820
Sofía Alexandra Caminos-CepedaSchool of Medicine, Universidad Pompeu Fabra, 08002 Barcelona, Spain.
Rubén NogueirasCIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-9976-9930
Carlos DiéguezCIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Ariel Iván Ruiz-ParraDepartment of Gynecology and Obstetrics, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.ORCID 0000-0001-7158-4742
Jorge Eduardo CaminosDepartment of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá 11001, Colombia.
Universidad Nacional de Colombia · COUniversidade de Santiago de Compostela · ESUniversidad de Los Andes · COUniversidad Nacional de La Plata · ARUniversitat Pompeu Fabra · ES

Funding

National University of Colombia HERMES code No. 51295
6 · The paper itself

Abstract

The Liver-Expressed Antimicrobial Peptide 2 (LEAP-2) has emerged as an endogenous GHS-R antagonist and blunts the orexigenic action of ghrelin. This study aimed to determine the Ghrelin/LEAP-2 ratio in humans and rats during pregnancy. In humans, we conducted a nested case-control study within an observational prospective cohort. Healthy and mild preeclamptic pregnant women were studied at each trimester of gestation and three months postpartum. In addition, a group of non-pregnant women was studied into the follicular and luteal phases of the menstrual cycle. Furthermore, Ghrelin/LEAP-2 ratio was investigated in non-pregnant rats and at different periods of rat pregnancy. Human and rat serum ghrelin and LEAP-2 levels were determined using the commercially available ELISA kits. The Ghrelin/LEAP-2 ratio peak around the second trimester of gestation in healthy pregnant women (p < 0.05). Additionally, there were no statistically significant differences in Ghrelin/LEAP-2 ratio between healthy and preeclamptic pregnant women at each trimester of gestation (p > 0.05). The Ghrelin/LEAP-2 ratio in pregnant rat reached the peak around mid-gestation with a similar pattern to the human pregnancy. LEAP-2 was visualized by immunohistochemistry in human term placenta and rat placentas on days 12, 16 and 21 of pregnancy. In conclusion, this study provides the first evidence of a Ghrelin/LEAP-2 ratio peak around the half-way point of pregnancy onwards during human and rat pregnancy, and it might be associated with increased rates of weight gain during pregnancy. Thus, this study suggests that LEAP-2 and Ghrelin/LEAP-2 ratio might play an important role in maternal physiology adaptation of weight gain during pregnancy.

Indexed as

Antimicrobial Cationic PeptidesBlood ProteinsGhrelinPregnancyAnimalsCase-Control StudiesFemaleHumansPlacentaPre-EclampsiaProspective StudiesRatsWeight GainAntimicrobial Cationic PeptidesBlood ProteinsGhrelinliver-expressed antimicrobial peptide 2, humanendogenous GHSR antagonistGhrelin/LEAP-2 ratiopregnancy

Identifiers

PMID36076912
PMCPMC9455743
OpenAlexW4293030670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.